KeyTec® TR-FRET Human SMARCA4 Binding Kit
Size:
Price: $ Inquire
CAT.: A1090015D
The KeyTec® TR‑FRET Human SMARCA4 Protein Binding Assay Kit is designed for screening ligands or inhibitors of wild‑type human SMARCA4 protein. This kit is a competitive immunoassay developed using KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation, high specificity, high sensitivity, and excellent reproducibility.
As illustrated in the schematic diagram below, a Solar Eu1‑conjugated anti‑Tag1 antibody specifically recognizes Tag1‑SMARCA4 protein, while HX2‑conjugated streptavidin (Streptavidin‑HX) recognizes biotinylated Bromodomain Ligand. When SMARCA4 protein binds to the Bromodomain Ligand, Solar Eu and HX are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of binding between the Bromodomain Ligand and SMARCA4 is determined by measuring the signal intensity at 665 nm. In the absence of competing inhibitors or ligands, the signal is at its maximum; as the concentration of added inhibitors or ligands increases, the signal gradually decreases. The TR‑FRET signal intensity is inversely proportional to the affinity of the inhibitor or ligand.
Standard curve
Validation results with different final concentrations of DMSO
Validation results in buffer systems with different pH values
| CAT. | Description | Size |
| A1090015D | KeyTec® TR-FRET Human SMARCA4 Binding Kit | 100 tests |
|
• 1 vial (8 μL/vial) Tag1 - SMARCA4 • 1 vial (8 μL/vial) Bromodomain Ligand • 1 vial (5 μL/vial) mAb anti - Tag1 - Solar Eu • 1 vial (5 μL/vial) Streptavidin - HX • 2 vials (2 mL/vial) SMARCA2/4 Binding Assay Diluent Buffer • 1 vial (2 mL/vial) SMARCA2/4 Detection Buffer |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60℃ or below |
The KeyTec® TR‑FRET Human SMARCA4 Protein Binding Assay Kit is designed for screening ligands or inhibitors of wild‑type human SMARCA4 protein. This kit is a competitive immunoassay developed using KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation, high specificity, high sensitivity, and excellent reproducibility.
As illustrated in the schematic diagram below, a Solar Eu1‑conjugated anti‑Tag1 antibody specifically recognizes Tag1‑SMARCA4 protein, while HX2‑conjugated streptavidin (Streptavidin‑HX) recognizes biotinylated Bromodomain Ligand. When SMARCA4 protein binds to the Bromodomain Ligand, Solar Eu and HX are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of binding between the Bromodomain Ligand and SMARCA4 is determined by measuring the signal intensity at 665 nm. In the absence of competing inhibitors or ligands, the signal is at its maximum; as the concentration of added inhibitors or ligands increases, the signal gradually decreases. The TR‑FRET signal intensity is inversely proportional to the affinity of the inhibitor or ligand.
Standard curve
Validation results with different final concentrations of DMSO
Validation results in buffer systems with different pH values
| CAT. | Description | Size |
| A1090015S | KeyTec® TR-FRET Human SMARCA4 Binding Kit | 500 tests |
|
• 1 vial (40 μL/vial) Tag1 - SMARCA4 • 1 vial (40 μL/vial) Bromodomain Ligand • 1 vial (25 μL/vial) mAb anti - Tag1 - Solar Eu • 1 vial (25 μL/vial) Streptavidin - HX • 1 bottle (20 mL/bottle) SMARCA2/4 Binding Assay Diluent Buffer • 1 bottle (20 mL/bottle) SMARCA2/4 Detection Buffer |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60℃ or below |
The KeyTec® TR‑FRET Human SMARCA4 Protein Binding Assay Kit is designed for screening ligands or inhibitors of wild‑type human SMARCA4 protein. This kit is a competitive immunoassay developed using KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation, high specificity, high sensitivity, and excellent reproducibility.
As illustrated in the schematic diagram below, a Solar Eu1‑conjugated anti‑Tag1 antibody specifically recognizes Tag1‑SMARCA4 protein, while HX2‑conjugated streptavidin (Streptavidin‑HX) recognizes biotinylated Bromodomain Ligand. When SMARCA4 protein binds to the Bromodomain Ligand, Solar Eu and HX are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of binding between the Bromodomain Ligand and SMARCA4 is determined by measuring the signal intensity at 665 nm. In the absence of competing inhibitors or ligands, the signal is at its maximum; as the concentration of added inhibitors or ligands increases, the signal gradually decreases. The TR‑FRET signal intensity is inversely proportional to the affinity of the inhibitor or ligand.
Standard curve
Validation results with different final concentrations of DMSO
Validation results in buffer systems with different pH values
| CAT. | Description | Size |
| A1090015L | KeyTec® TR-FRET Human SMARCA4 Binding Kit | 5,000 tests |
|
• 1 vial (400 μL/vial) Tag1 - SMARCA4 • 1 vial (400 μL/vial) Bromodomain Ligand • 1 vial (250 μL/vial) mAb anti - Tag1 - Solar Eu • 1 vial (250 μL/vial) Streptavidin - HX • 1 bottle (200 mL/bottle) SMARCA2/4 Binding Assay Diluent Buffer • 1 bottle (120 mL/bottle) SMARCA2/4 Detection Buffer |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60℃ or below |
English
![KeyTec® TR-FRET GDP loaded KRAS[G12D]/SOS1 Binding Assay kit](/uploads/image/20260713/A1090001S.webp "KeyTec® TR-FRET GDP loaded KRAS[G12D]/SOS1 Binding Assay kit")
